{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:39:23Z","timestamp":1789925963070,"version":"4.0.1"},"reference-count":137,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.gastha.2023.06.014","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T05:38:16Z","timestamp":1689572296000},"page":"276-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-0022","authenticated-orcid":false,"given":"Katerina","family":"Roma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni-Marie","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Dossaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankoor","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Minacapelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"43","key":"10.1016\/j.gastha.2023.06.014_bib3","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.3748\/wjg.v27.i43.7497","article-title":"Hepatitis B: who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases","volume":"27","author":"Kawanaka","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib4","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"17","key":"10.1016\/j.gastha.2023.06.014_bib5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.gastha.2023.06.014_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/hepr.13504","article-title":"Drafting committee for hepatitis management guidelines, the Japan society of Hepatology. Japan society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update","volume":"50","year":"2020","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib9","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 Update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib11","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/v14040657","article-title":"HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure","volume":"14","author":"Moini","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis B: accessibility, durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol J"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/apt.15581","article-title":"Review article: clinical pharmacology of current and investigational hepatitis B virus therapies","volume":"51","author":"Smolders","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/cid\/ciab405","article-title":"Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States","volume":"74","author":"Toy","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and testing for hepatitis B virus infection: CDC recommendations \u2014 United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.ackd.2015.06.003","article-title":"Glomerular diseases associated with hepatitis B and C","volume":"22","author":"Gupta","year":"2015","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/apt.15132","article-title":"Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's\u00a0lymphoma and multiple myeloma","volume":"49","author":"Su","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.gastha.2023.06.014_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025503","article-title":"Chronic hepatitis B stigma in Ghana: a qualitative study with patients and providers","volume":"9","author":"Adjei","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.gastha.2023.06.014_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-7525-2-32","article-title":"Patients' needs, satisfaction, and health related quality of life: towards a comprehensive model","volume":"2","author":"Asadi-Lari","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/jvh.13451","article-title":"Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV","volume":"28","author":"Younossi","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2023.06.014_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2020.10.005","article-title":"Health-related quality of life in Cuban patients with chronic liver disease: a real-world experience","volume":"22","author":"Castellanos-Fern\u00e1ndez","year":"2021","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures","volume":"27","author":"Prinsen","year":"2018","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77886-2","article-title":"Depressive symptoms and risk of liver-related mortality in individuals with hepatitis B virus infection: a cohort study","volume":"10","author":"Cho","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.gastha.2023.06.014_bib25","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.gastha.2023.06.014_bib26","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1111\/j.1537-2995.2009.02322.x","article-title":"Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion","volume":"49","author":"Kleinman","year":"2009","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/trf.15103","article-title":"Interpretation of pathogen load in relationship to infectivity and pathogen reduction efficacy","volume":"59","author":"McCullough","year":"2019","journal-title":"Transfusion"},{"issue":"12","key":"10.1016\/j.gastha.2023.06.014_bib28","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1002\/jmv.21320","article-title":"Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes","volume":"80","author":"Tabuchi","year":"2008","journal-title":"J\u00a0Med Virol"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1537-2995.2001.41091093.x","article-title":"Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors","volume":"41","author":"Yotsuyanagi","year":"2001","journal-title":"Transfusion"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib30","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1537-2995.2009.02188.x","article-title":"Transient occult hepatitis B virus infection in a blood donor with high viremia","volume":"49","author":"Bremer","year":"2009","journal-title":"Transfusion"},{"issue":"7","key":"10.1016\/j.gastha.2023.06.014_bib31","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/trf.12096","article-title":"Infectivity of blood products from donors with occult hepatitis B virus infection","volume":"53","author":"Allain","year":"2013","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41575-020-00398-x","article-title":"Extending treatment eligibility for chronic hepatitis B virus infection","volume":"18","author":"McNaughton","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2023.06.014_bib33","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","article-title":"Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention","volume":"34","author":"Lavanchy","year":"2005","journal-title":"J\u00a0Clin Virol"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2023.06.014_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1478-3231.2008.01933.x","article-title":"Hepatitis B and pregnancy: an underestimated issue","volume":"29","author":"Jonas","year":"2009","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib35","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","article-title":"Long-term outcomes in hepatitis B: the REVEAL-HBV study","volume":"11","author":"Chen","year":"2007","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.gastha.2023.06.014_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110143","article-title":"The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology","volume":"9","author":"Goyal","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib38","first-page":"205","article-title":"Management of hepatitis B virus infection during pregnancy","volume":"60","author":"Vodkin","year":"2014","journal-title":"Minerva Gastroenterol Dietol"},{"issue":"14","key":"10.1016\/j.gastha.2023.06.014_bib39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM197604012941402","article-title":"e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants","volume":"294","author":"Okada","year":"1976","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","article-title":"The e antigen and vertical transmission of hepatitis B surface antigen","volume":"105","author":"Beasley","year":"1977","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.gastha.2023.06.014_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2016.02.003","article-title":"Management of mother-to-child transmission of hepatitis B virus: propositions and challenges","volume":"77","author":"Yi","year":"2016","journal-title":"J\u00a0Clin Virol"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.5694\/j.1326-5377.2009.tb02524.x","article-title":"Perinatal transmission of hepatitis B virus: an Australian experience","volume":"190","author":"Wiseman","year":"2009","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib43","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1365-2893.2011.01492.x","article-title":"Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers","volume":"19","author":"Zou","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2023.06.014_bib44","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/jpids\/piu064","article-title":"Prevention of perinatal hepatitis B virus transmission","volume":"3","author":"Nelson","year":"2014","journal-title":"J\u00a0Pediatric Infect Dis Soc"},{"issue":"33","key":"10.1016\/j.gastha.2023.06.014_bib45","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.3748\/wjg.v18.i33.4517","article-title":"Management of chronic hepatitis B in pregnancy","volume":"18","author":"Han","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2023.06.014_bib46","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0168-8278(03)00141-7","article-title":"Epidemiology of hepatitis B in Europe and worldwide","volume":"39","author":"Alter","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"8274","key":"10.1016\/j.gastha.2023.06.014_bib47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(82)92636-8","article-title":"Interruption of hepatitis B transmission by modification of a gynaecologist's surgical technique","volume":"1","author":"Carl","year":"1982","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gastha.2023.06.014_bib48","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0025-7125(16)30493-X","article-title":"The emergence of hepatitis B as a sexually transmitted disease","volume":"74","author":"Alter","year":"1990","journal-title":"Med Clin North Am"},{"issue":"6","key":"10.1016\/j.gastha.2023.06.014_bib49","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.gastha.2023.06.014_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1874357901812010026","article-title":"Epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) related hepatocellular carcinoma","volume":"12","author":"Petruzziello","year":"2018","journal-title":"Open Virol J"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib52","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib53","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib54","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib55","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.14309\/ajg.0000000000001271","article-title":"Initial evaluation, long-term monitoring, and hepatocellular carcinoma surveillance of chronic hepatitis B in routine practice: a nationwide US Study","volume":"116","author":"Tran","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib56","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/v14050986","article-title":"Hepatitis B virus-associated hepatocellular carcinoma","volume":"14","author":"Rizzo","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib57","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cgh.2022.01.047","article-title":"The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States","volume":"21","author":"Tayob","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib58","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib60","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/ph14080735","article-title":"GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients","volume":"14","author":"Schotten","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.gastha.2023.06.014_bib61","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3390\/cancers13071729","article-title":"Tertiary prevention of HCC in chronic hepatitis B or C infected patients","volume":"13","author":"Teng","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib62","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma","volume":"51","author":"Wu","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.gastha.2023.06.014_bib63","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1572-0241.2008.01872.x","article-title":"Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection","volume":"103","author":"Hung","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib64","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1016::AID-CNCR10>3.0.CO;2-V","article-title":"Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma","volume":"88","author":"Kubo","year":"2000","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.gastha.2023.06.014_bib65","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study","volume":"31","author":"Yin","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.gastha.2023.06.014_bib66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jvh.13766","article-title":"Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: a systematic review and meta-analysis","volume":"30","author":"Giri","year":"2023","journal-title":"J\u00a0Viral Hepat"},{"issue":"21","key":"10.1016\/j.gastha.2023.06.014_bib67","first-page":"6247","article-title":"Extrahepatic manifestations of chronic HBV infection and the\u00a0role\u00a0of antiviral therapy","volume":"11","author":"Mazzaro","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib68","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","article-title":"Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients","volume":"74","author":"Guillevin","year":"1995","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jhep.2005.05.029","article-title":"Hepatitis B virus genotypes and extrahepatic manifestations","volume":"43","author":"Cacoub","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rdc.2009.03.006","article-title":"Hepatitis B-related autoimmune manifestations","volume":"35","author":"Cacoub","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-021-00983-2","article-title":"Clinical approach to diagnosis and therapy of polyarteritis nodosa","volume":"23","author":"Ho\u010devar","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib73","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.amjmed.2015.02.017","article-title":"Cryoglobulinemia vasculitis","volume":"128","author":"Cacoub","year":"2015","journal-title":"Am J Med"},{"issue":"Suppl 2","key":"10.1016\/j.gastha.2023.06.014_bib74","first-page":"SII20","article-title":"HCV and cryoglobulinemic vasculitis","volume":"69","author":"Ferri","year":"2002","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-018-0009-4","article-title":"Cryoglobulinaemia","volume":"4","author":"Roccatello","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.gastha.2023.06.014_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102313","article-title":"New insights in cryoglobulinemic vasculitis","volume":"105","author":"Silva","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14309\/ajg.0000000000001575","article-title":"Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease","volume":"117","author":"Cacoub","year":"2022","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13075-018-1623-y","article-title":"Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis","volume":"20","author":"Chen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.gastha.2023.06.014_bib79","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2147\/IJGM.S318087","article-title":"Hepatitis B virus-related glomerulonephritis with positive and negative serum HBsAg: different clinicopathologic characteristics of two clinical subtypes","volume":"14","author":"Yu","year":"2021","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.gastha.2023.06.014_bib80","first-page":"S40","article-title":"Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults","volume":"35","author":"Lai","year":"1991","journal-title":"Kidney Int Suppl"},{"issue":"4-5","key":"10.1016\/j.gastha.2023.06.014_bib81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000431331","article-title":"Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy","volume":"41","author":"Xie","year":"2015","journal-title":"Am J Nephrol"},{"issue":"15","key":"10.1016\/j.gastha.2023.06.014_bib82","first-page":"3450","article-title":"Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review","volume":"10","author":"Rong","year":"2019","journal-title":"J\u00a0Cancer"},{"issue":"9","key":"10.1016\/j.gastha.2023.06.014_bib83","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.gastha.2023.06.014_bib84","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J\u00a0Infect Dis"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib85","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global\u00a0prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib86","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib87","doi-asserted-by":"crossref","first-page":"12","DOI":"10.20411\/pai.v1i1.72","article-title":"Hepatitis delta virus detected in salivary glands of Sj\u00f6gren's Syndrome patients and recapitulates a Sj\u00f6gren's Syndrome-like phenotype in\u00a0vivo","volume":"1","author":"Weller","year":"2016","journal-title":"Pathog Immun"},{"issue":"7-8","key":"10.1016\/j.gastha.2023.06.014_bib88","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/0753-3322(96)82663-1","article-title":"Autoantibodies in hepatitis delta","volume":"49","author":"Philipp","year":"1995","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib89","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2893.2011.01462.x","article-title":"Characterizing hepatitis B stigma in Chinese immigrants","volume":"19","author":"Cotler","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2023.06.014_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1910292","article-title":"Hepatitis B stigma and knowledge among Vietnamese in Ho chi Minh city and Chicago","volume":"2016","author":"Dam","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib92","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib93","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastha.2023.06.014_bib94","doi-asserted-by":"crossref","first-page":"477","DOI":"10.15585\/mmwr.mm7113a1","article-title":"Hepatitis B vaccination in adults aged 19\u201359 years: updated recommendations of the advisory committee on immunization practices \u2014 United States, 2022","volume":"71","author":"Weng","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gastha.2022.10.004","article-title":"It is time for a simplified approach to hepatitis B elimination","volume":"2","author":"Dieterich","year":"2023","journal-title":"Gastro Hep Adv"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib96","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7018","article-title":"Racial disparities in treatment initiation and outcomes of chronic hepatitis B virus infection in North America","volume":"6","author":"Khalili","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib97","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3390\/v15040997","article-title":"Evidence for benefits of early treatment initiation for chronic hepatitis B","volume":"15","author":"Lim","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.gastha.2023.06.014_bib98","article-title":"Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation","volume":"35","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/INF.0000000000001387","article-title":"Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation","volume":"36","author":"Jacobson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.gastha.2023.06.014_bib100","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/cid\/ciw159","article-title":"In utero tenofovir exposure is not associated with fetal long bone growth","volume":"62","author":"Jao","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000001359","article-title":"Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis","volume":"76","author":"Nachega","year":"2017","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib102","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1128\/AAC.00514-10","article-title":"Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2","volume":"55","author":"Benaboud","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib103","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0b013e3182a921eb","article-title":"Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life","volume":"65","author":"Mirochnick","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"RR-8","key":"10.1016\/j.gastha.2023.06.014_bib104","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"issue":"RR-16","key":"10.1016\/j.gastha.2023.06.014_bib105","first-page":"1","article-title":"A\u00a0comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep"},{"issue":"11","key":"10.1016\/j.gastha.2023.06.014_bib106","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1128\/JVI.00096-07","article-title":"Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues","volume":"81","author":"Blanchet","year":"2007","journal-title":"J\u00a0Virol"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib107","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2023.06.014_bib108","first-page":"S224","article-title":"Bulevirtide improves health related quality life measured by EQ-5D VAS in patients with chronic hepatitis delta: an exploratory analysis of a phase 3 trial at 48 weeks","volume":"76","author":"Buti","year":"2022","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.gastha.2023.06.014_bib109","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of chronic hepatitis D with bulevirtide-A fight against two foes-an update","volume":"11","author":"Ferenci","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.gastha.2023.06.014_bib110","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1517\/14656561003637659","article-title":"Treatment of HBV\/HCV coinfection","volume":"11","author":"Potthoff","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.gastha.2023.06.014_bib111","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib112","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.gastha.2023.06.014_bib114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.14356","article-title":"Future treatments for hepatitis delta virus infection","volume":"40","author":"Asselah","year":"2020","journal-title":"Liver Int"},{"issue":"15","key":"10.1016\/j.gastha.2023.06.014_bib115","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.gastha.2023.06.014_bib116","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0168-8278(16)00626-7","article-title":"Treatment of chronically HBV-infected chimpanzees with RNA interference therapeutic ARC-520 LED to potent reduction of viral MRNA, DNA and proteins without observed drug resistance","volume":"64","author":"Xu","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib117","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S0168-8278(16)00606-1","article-title":"Differential reductions in viral antigens expressed from CCCDNAVS integrated DNA in treatment na\u00efve HBEAG positive and negative patients with chronic HBV after RNA interference therapy with ARC-520","volume":"64","author":"Yuen","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib118","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib119","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","article-title":"Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.gastha.2023.06.014_bib120","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/hep.31920","article-title":"Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B","volume":"74","author":"Gane","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.gastha.2023.06.014_bib121","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.gastha.2023.06.014_bib122","first-page":"223A","article-title":"Dual-gRNAs and gRNA-microRNA (miRNA)-gRNA ternary cassette combined CRISPR\/Cas9 system and RNAi approach promotes the clearance of HBV cccDNA","volume":"62","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2023.06.014_bib123","first-page":"782A","article-title":"The combination effects of CRISPR\/Cas9 and APOBEC3B editing on HBV cccDNA formation","volume":"66","author":"Shi","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib124","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11901-020-00523-z","article-title":"Role of core\/capsid inhibitors in functional cure strategies for chronic hepatitis B","volume":"19","author":"Hui","year":"2020","journal-title":"Curr Hepatol Rep"},{"issue":"12","key":"10.1016\/j.gastha.2023.06.014_bib125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.gastha.2023.06.014_bib126","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.gastha.2023.06.014_bib127","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gastha.2023.06.014_bib128","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a Phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib129","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2022.04.005","article-title":"Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection","volume":"77","author":"Yuen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.virol.2006.09.006","article-title":"Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and noninfectious subviral particles","volume":"359","author":"Franke","year":"2007","journal-title":"Virology"},{"issue":"16","key":"10.1016\/j.gastha.2023.06.014_bib131","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1128\/JVI.00561-08","article-title":"Properties of subviral particles of hepatitis B virus","volume":"82","author":"Chai","year":"2008","journal-title":"J\u00a0Virol"},{"issue":"3","key":"10.1016\/j.gastha.2023.06.014_bib132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/v9030056","article-title":"Complete and incomplete hepatitis B virus particles: formation, function, and application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib133","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.gastha.2023.06.014_bib134","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2023.06.014_bib135","author":"Gane"},{"issue":"39","key":"10.1016\/j.gastha.2023.06.014_bib136","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.gastha.2023.06.014_bib137","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161313","article-title":"Antiviral efficacy and host innate immunity associated with SB 9200 treatment in the Woodchuck Model of chronic hepatitis B","volume":"11","author":"Korolowicz","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib138","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","article-title":"Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B","volume":"60","author":"Chen","year":"2011","journal-title":"Inflamm Res"},{"issue":"1","key":"10.1016\/j.gastha.2023.06.014_bib139","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s13187-011-0252-9","article-title":"Destigmatizing hepatitis B in the asian American community: lessons learned from the san Francisco Hep B free Campaign","volume":"27","author":"Yoo","year":"2012","journal-title":"J\u00a0Cancer Educ"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232300105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277257232300105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:36:44Z","timestamp":1757417804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277257232300105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"alternative-id":["S277257232300105X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.06.014","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}